Abstracts tagged "Rheumatoid arthritis (RA) and sleep apnea"

Abstract Number: 2849 • 2018 ACR/ARHP Annual Meeting
Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis
Patricia Katz¹, Sofia Pedro² and Kaleb Michaud^2,3, ¹University of California San Francisco, San Francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Self-reported sleep disturbances (SDs) are common in RA. Most studies of sleep in RA have focused on SDs in general. Obstructive sleep apnea (OSA)…
Abstract Number: 1507 • 2015 ACR/ARHP Annual Meeting
Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis Patients: The Frequency and Associated Disease Features
Fabian Dario Sinigaglia¹, Rafael Chaparro del Moral¹, Silvia Papasidero¹, Oscar Luis Rillo¹, José Angel Caracciolo², María Alejandra Medina¹, Analia Dellepiane³, Cecilia Zaffarana⁴, Maria de los Angeles Correa⁵, Luciana Casalla⁶, Lucía Zarate⁶, Nieves Capozzi⁷, María Victoria Martire⁸, Marta Mamani⁸, Damaris Alvarez⁹, Eduardo Kerzberg⁹ and José Luis Velasco Zamora¹⁰, ¹Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ²Rhematology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ³CEMEC, Santa Fe, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital Posadas, Buenos Aires, Argentina, ⁷'Irigoyen 1418. CABA, Hospital Posadas, Buenos Aires, Argentina, ⁸Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Rheumatology Section, Hospital General de Agudos Dr. J. M. Ramos Mejía, Buenos Aires, Argentina, ¹⁰Reumatología al Sur, Berazategui, Argentina
Background/Purpose: Obstructive Sleep Apnea Syndrome (OSA) affects 2-4% of the population and it has been observed in rheumatoid arthritis (RA) patients in up to 30.8%.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].